Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Inclusion criteria

• ✓. Written informed consent.
• ✓. Patients of either gender, aged ≥ 18 years.
• ✓. Women of childbearing potential (not surgically sterile or less than 2 years postmenopausal) must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 6 months after the last dose. Acceptable methods of contraception include abstinence, or double contraception: steroidal contraceptive (oral, transdermal, implanted, and injected) in conjunction with a barrier method (intrauterine device, condom etc.).
• ✓. Male patients must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 6 months after the last activity administration.
• ✓. Karnofsky performance score ≥ 60.
• ✓. Life expectancy of at least 6 months.
• ✓. Histologically confirmed diagnosis of -
• ✓. Documentation of progressive disease based on RECIST v1.1 under prior anti-tumor therapy within 6 months of entry in the study (although the progression might have occurred more than 6 months before study entry). Patients should not have received further anti-tumor therapy once disease progression is documented. The images of this evaluation should be available for TGR evaluation.